• 1
    Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case control study of risks versus benefits. Am. J. Psychiatry 2004; 161: 700706.
  • 2
    Harrington M, Lelliott C, Paton C, Okocha C, Duffett R, Sensky T. The results of a multi center audit of the prescribing of antipsychotic drugs for inpatients in UK. Psychiatr. Bull. 2002; 26: 414418.
  • 3
    Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 1988; 45: 7991.
  • 4
    Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br. J. Psychiatry 2006; 188: 122127.
  • 5
    National Institute for Health and Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care 2009, [Cited March 2009.] Available from URL:
  • 6
    Lehman AF, Lieberman JA. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. Arlington, APA Practice Guidelines, 2004.
  • 7
    Chong MY, Tan HC, Fujii S et al. Antipsychotic drug prescription for schizophrenia in East Asia: Rationale for change. Psychiatry Clin. Neurosci. 2004; 58: 6167.
  • 8
    Shinfuku N, Tan C. Pharmacotherapy for schizophrenic inpatients in East Asia – Changes and challenges. Int. Rev. Psychiatry 2008; 20: 460468.
  • 9
    Craig TJ, Bracken J. An epidemiologic study of prn/stat medication use in a state psychiatric hospital. Ann. Clin. Psychiatry 1995; 7: 5764.
  • 10
    Chakrabarti A, Whicher E, Morrison M, Douglas-Hall P. ‘As required’ medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst. Rev. 2007; 3: CD003441. (Cited March 2007). Available from URL:
  • 11
    Curtis J, Capp K. Administration of ‘as needed’ psychotropic medication: A retrospective study. Int. J. Ment. Health Nurs. 2003; 12: 229234.
  • 12
    Craven JL, Voore PM, Voineskos G. PRN medication for psychiatric inpatients. Can. J. Psychiatry 1987; 32: 199203.
  • 13
    Geffen J, Sorensen L, Stokes J, Cameron A, Roberts MS, Geffen L. Pro re nata medication for psychoses: An audit of practice in two metropolitan hospitals. Aust. N. Z. J. Psychiatry 2002; 36: 649656.
  • 14
    Stein-Parbury J, Reid K, Smith N, Mouhanna D, Lamout F. Use of pro re nata medications in acute inpatient care. Aust. N. Z. J. Psychiatry 2008; 42: 283292.
  • 15
    Baker JA, Lovell K, Harris N. Mental health professionals' psychotropic pro re nata (p.r.n.) medication practices in acute mental health care: A qualitative study. Gen. Hosp. Psychiatry 2007; 29: 163168.
  • 16
    Bowden MF. Audit: Prescription of ‘as required’ (p.r.n.) medication in an in-patient setting. Psychiatr. Bull. 1999; 23: 413416.
  • 17
    Milton J, Lawton J, Smith M, Buckley A. Hidden high dose antipsychotic prescribing: effects of prn doses. Psychiatr. Bull. 1998; 22: 675677.
  • 18
    Paton C, Barnes TRE, Cavanagh M, Taylor D, Lelloit P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br. J. Psychiatry 2008; 192: 435439.
  • 19
    Baker JA, Lovell K, Harris N. A best-evidence synthesis review of the administration of psychotropic pro re nata (PRN) medication in inpatient mental health settings. J. Clin. Nurs. 2008; 17: 11221131.
  • 20
    Inagaki A, Inada S. Dose equivalence of psychotropic drugs, 2006 version. Rinsho Seishin Yakuri 2006; 9: 14431447 (in Japanese).
  • 21
    Norusis MJ, SPSS inc. SPSS 11.0 Guide to Data Analysis. Prentice Hall, Upper Saddle River, NJ, 2002.
  • 22
    McLearen S, Browne FWA, Taylor PL. A study of psychotropic medication given ‘as required’ in a regional secure unit. Br. J. Psychiatry 1990; 156: 732735.
  • 23
    Usher K, Holmes C, Lindsay D, Luck L. PRN psychotropic medications: the need for nursing research. Contemp. Nurs. 2003; 14: 248257.
  • 24
    Geffen J, Cameron A, Sorensen L, Stokes J, Roberts MS, Geffen L. Pro re nata medication for psychoses: the knowledge and beliefs of doctors and nurses. Aust. N. Z. J. Psychiatry 2002; 36: 642648.
  • 25
    Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br. J. Psychiatry 2005; 187: 243247.
  • 26
    National Institute for Health and Clinical Excellence (NICE). Violence, the short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments [Cited March 2006.] Available from URL:
  • 27
    Campbell R, Simpson G. Alternative approaches in the treatment of psychotic agitation. Psychosomatics 1986; 27 (Suppl. 1): 2326.
  • 28
    Wolkowitz O, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am. J. Psychiatry 1991; 148: 714726.
  • 29
    Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J. Clin. Psychiatry 2001; 62: 153157.
  • 30
    Canas F. Management of agitation in the acute psychotic patient – efficacy without excessive sedation. Eur. Neuropsychopharmacol. 2007; 17: s108s114.
  • 31
    Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: A content analysis of internet data. Acta Psychiatr. Scand. 2009; 120: 102111.
  • 32
    Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. Increased risk of extrapyramidal side effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr. Scand. 2006; 113: 135141.
  • 33
    Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risk of current combinations. Acta Psychiatr. Scand. 2002; 106: 323330.
  • 34
    Weiden PJ, Preskorn SH, Fahnestock PA et al. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a road map. J. Clin. Psychiatry 2007; 68 (Suppl. 7): 148.
  • 35
    Conley RR, Kelly DL. Drug-drug interactions associated with second generation antipsychotics: considerations for clinicians and patients. Psychopharmacol. Bull. 2007; 40: 7797.
  • 36
    Demczar D, Levin G. Use of atypical antipsychotics on an as needed basis. J. Pharm. Tech. 1996; 12: 145148.
  • 37
    Baker JA, Lovell K, Harris N, Campbell M. Multidisciplinary consensus of best practice for pro re nata (PRN) psychotropic medications within acute mental health settings: A Delphi study. J. Psychiatr. Ment. Health Nurs. 2007; 14: 478484.
  • 38
    Thapa PB, Palmer SL, Owen RR, Huntley AL, Clardy JA, Miller LH. PRN (as needed) orders and exposure of psychiatric inpatients to unnecessary psychotropic medications. Psychiatr. Serv. 2003; 54: 12821286.